ABSTRACT
Askin's tumor is a rare neoplasm of the chest wall with a dismalprognosis. We report the case of 16-year-old girl presenting with a painful mass on the right anterolateral chest wall. The patient underwent radical mass resection. Histopathology revealed an Askin's tumor infiltrating the 5th ipsilateral rib and pleura. The girl subsequently received postoperative chemo-radio therapy with a satisfactory response. This is the first reported case of Askin's tumor in Greece and we focus on the clinical, radiological,pathological and therapeutic aspects of this rare entity.
Subject(s)
Thoracic Neoplasms/pathology , Thoracic Wall/pathology , Adolescent , Biopsy, Fine-Needle , Chemotherapy, Adjuvant , Female , Humans , Radiotherapy, Adjuvant , Thoracic Neoplasms/therapy , Thoracic Wall/surgery , Thoracotomy , Tomography, X-Ray Computed , Treatment OutcomeSubject(s)
Conjunctivitis, Bacterial/etiology , Conjunctivitis, Bacterial/microbiology , Infectious Disease Transmission, Patient-to-Professional , Tuberculosis, Ocular/etiology , Adult , Conjunctivitis, Bacterial/prevention & control , Humans , Infectious Disease Transmission, Patient-to-Professional/prevention & control , Male , Protective Devices , Radiology, Interventional , Tuberculosis, Ocular/prevention & controlABSTRACT
It is now well established that solid tumors depend on angiogenesis. Promoters and inhibitors of angiogenesis are in balance and antiangiogenic strategies aim at repressing the angiogenic process, thus retarding solid tumor progression. Recent data suggest the importance of angiogenesis in hematologic malignancies and several studies reveal an increased angiogenesis in active multiple myeloma. Angiogenesis seems to be a prominent feature of MM progression, and seems to be correlated with the prognosis and the resistance of MM to chemotherapy. Numerous cell populations and cytokines are involved in angiogenesis in multiple myeloma and antiangiogenic therapy with thalidomide is effective in patients with refractory or relapsed disease. The combination of thalidomide and of other immunomodulatory agents with other therapeutic regimens could lead to more effective management of patients with multiple myeloma.
